Abstract

BackgroundGlucocorticoid-associated osteonecrosis is an intractable condition, making the establishment of preventative strategies of particular importance. Recently various studies using mesenchymal stem cells (MSC) have been conducted. Using a rabbit glucocorticoid-associated osteonecrosis model we administered green fluorescent protein (GFP)-labeled MSC intravenously to investigate their effect on osteonecrosis.MethodsA rabbit osteonecrosis model in which methylprednisolone (MP) 20 mg/kg was injected into the gluteus of a Japanese white rabbit was used. Simultaneously with MP, MSC labeled with GFP (GFP-labeled MSC) were injected intravenously. Fourteen days later the animals were killed (MSC(+)/MP(+)/14d), femurs were extracted, and the prevalence of osteonecrosis was determined histopathologically. Also, animals were killed 3 days after simultaneous administration of GFP-labeled MSC and MP (MSC(+)/MP(+)/3d), and western blotting (WB) for GFP was performed of the femur, liver, kidney, lung, blood vessel, and vertebra, in addition to immunohistochemical study of femur. As a control for the histopathological study, animals were killed 14 days after MP administration and intravenous vehicle injection (MSC(−)/MP(+)/14d). For WB, animals were killed 3 days after intravenous GFP-labeled MSC administration and vehicle injection into the gluteus (MSC(+)/MP(−)/3d).ResultsIn MSC(−)/MP(+)/14d osteonecrosis was found in 7 of 10 rabbits (70%), while in MSC(+)/MP(+)/14d, partial bone marrow necrosis was found in only 1 rabbit (12.5%); osteonecrosis was not found in 7 of 8 rabbits (p < 0.05). WB showed expression of GFP in the femur, not in the liver, kidney, lung, blood vessel, or vertebra, of MSC(+)/MP(+)/3d; expression of GFP-labeled MSC was absent in the femur of MSC(+)/MP(−)/3d. In the immunohistochemical study of MSC(+)/MP(+)/3d, homing of GFP-labeled MSC was noted perivascularly in the femur, but not in MSC(+)/MP(−)/3d.ConclusionsWith transvenous MSC administration a significant prophylactic effect against glucocorticoid-associated osteonecrosis was found. Direct administration of MSC to the site of tissue injury requires highly invasive surgery. In contrast, as shown here the simple and hardly invasive intravenous administration of MSC may succeed in preventing osteonecrosis.

Highlights

  • Glucocorticoid-associated osteonecrosis is an intractable condition, making the establishment of preventative strategies of particular importance

  • An additional figure file shows this in more detail

  • Inhibition of osteonecrosis by mesenchymal stem cells (MSC) Since in this model an osteonecrosis development rate of 70% 14 days after MP administration has been reported [1, 18,19,20], the histopathological study was conducted at this time point

Read more

Summary

Introduction

Glucocorticoid-associated osteonecrosis is an intractable condition, making the establishment of preventative strategies of particular importance. A glucocorticoid-associated femoral head necrosis leads to destruction of the femoral head Once it develops and the femoral head is collapsed, surgery, such as osteotomy or artificial joint placement, becomes the sole option to treat the associated pain. This highlights the importance of the prevention, though at present no effective strategies to prevent osteonecrosis in patients who require therapeutic steroids have yet been established. With regard to prevention the administrations of vitamin E, pitavastatin, and other agents have been attempted [4, 5] With agents such as vitamin E and pitavastatin an osteonecrosis inhibitory effect is obtained (about 34% inhibition with vitamin E, about 53% with statin administration), sufficient inhibition has not yet been achieved [6, 7]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call